Geoff A. Green
Longeveron Inc.
Also published as: Geoff Green
3 papersOpenAlex
- Laromestrocel
- Allogeneic mesenchymal stem cells
- Mobility limitation
- Aging frailty
- Frailty syndrome
- Immune response
- TEK
- Angiopoietin–TIE2 signaling
Is this you? Claim this profile
Papers
Cell Stem Cell
Randomized phase 2b dose-escalation trial of stem cell therapy with laromestrocel for aging frailty
Randomized trial in 148 peopleInterventions
The Journals of Gerontology, Series A
Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Randomized trial in 30 peopleInterventions
The Journals of Gerontology, Series A
Allogeneic Human Mesenchymal Stem Cell Infusions for Aging Frailty
Trial in peopleInterventions
Works at
Sources: doi.org